Equillium announces plans to initiate phase 3 pivotal study of itolizumab in first-line treatment of acute graft-versus-host disease following end-of-phase 1 meeting with the fda

Single pivotal phase 3 study in acute graft-versus-host disease to support filing of biologics license application

EQ Ratings Summary

EQ Quant Ranking